
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. has raised its full-year 2025 pro forma net revenue guidance to a range of $390–$410 million, reflecting stronger-than-expected adoption of its product DefenCath along with early contributions from the Melinta portfolio. The company projects fourth-quarter net revenue between $115 million and $135 million, indicating consistent momentum as they approach year-end and highlighting robust commercial execution. Furthermore, Cormedix's increased guidance for fully synergized pro forma adjusted EBITDA to $220–$240 million underscores its solid financial performance and improving operational metrics.
Bears say
Cormedix Inc faces significant pricing pressure as DefenCath's price is expected to drop substantially with the second phase of the TDAPA reevaluation set for July 2026. The uncertainty surrounding TDAPA pricing could hinder sales projections of DefenCath, especially in a competitive landscape that includes lower-cost generic alternatives like Heparin. Additionally, while there are suggested growth opportunities within the Niyadas product range, the overall dependence on a single product within a narrow market confines presents substantial risk to the company's financial stability and long-term outlook.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares